• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

Neurocrine Biosciences Inc

+ Add to Watchlist


9.556 EUR 0.183 1.95%

As of 02:16:05 ET on 04/16/2014.

Snapshot for Neurocrine Biosciences Inc (NB3)

Open: 9.382 Day's Range: 9.382 - 9.556 Volume: 0
Previous Close: 9.373 52wk Range: 6.334 - 14.705 1-Yr Rtn: +8.52%

Stock Chart for NB3

No chart data available.
  • NB3:GR 9.556
  • 1D
  • 1M
  • 1Y
Interactive NB3 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for NB3

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.8410
Est. PEG Ratio -
Market Cap (M EUR) 720.06
Shares Outstanding (M) 75.35
30 Day Average Volume 28
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/02/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for NB3

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for NB3

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.

Kevin C GormanPresident/CEOTimothy P CoughlinChief Financial Officer
Christopher F O'BrienChief Medical OfficerHaig P BozigianChief Development Officer
More Company Profile & Key Executives for NB3

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Links
sec ||= nil